UBS ASSET MANAGEMENT AMERICAS LLC - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 132 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.0%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$223,496,000
-9.6%
65,7340.0%0.00%
Q2 2018$247,160,000
-8.1%
65,7340.0%0.00%
Q1 2018$268,852,000
+29.5%
65,734
+47.3%
0.00%
Q4 2017$207,548,000
-25.2%
44,634
+14.3%
0.00%
Q3 2017$277,304,000
+0.1%
39,057
+1.9%
0.00%
Q2 2017$277,024,000
+17.7%
38,316
+0.3%
0.00%
Q1 2017$235,398,000
+104988.4%
38,2140.0%0.00%
Q4 2016$224,000
-42.7%
38,214
-48.2%
0.00%
Q3 2016$391,000
-19.9%
73,7140.0%0.00%
-100.0%
Q2 2016$488,000
+31.2%
73,714
-7.5%
0.00%
Q1 2016$372,000
-14.5%
79,700
-7.5%
0.00%
Q4 2015$435,000
-90.4%
86,200
-93.3%
0.00%
-100.0%
Q3 2015$4,535,000
-76.5%
1,288,381
-33.2%
0.01%
-72.2%
Q2 2015$19,262,000
-18.1%
1,930,099
+4.5%
0.02%
-21.7%
Q1 2015$23,519,000
+57.8%
1,847,496
+75.4%
0.02%
+64.3%
Q4 2014$14,906,000
+6.3%
1,053,396
+3.3%
0.01%0.0%
Q3 2014$14,024,000
-28.6%
1,019,896
-20.1%
0.01%
-30.0%
Q2 2014$19,642,000
-6.0%
1,277,096
+4.1%
0.02%
-9.1%
Q1 2014$20,906,000
+189.5%
1,226,896
+120.0%
0.02%
+175.0%
Q4 2013$7,222,000
+2884.3%
557,700
+2223.8%
0.01%
Q3 2013$242,000
+35.2%
24,0000.0%0.00%
Q2 2013$179,00024,0000.00%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Old West Investment Management, LLC 1,068,719$3,633,0001.50%
Abrams Capital Management 9,108,867$30,970,0000.82%
Baupost Group 25,791,678$87,692,0000.67%
Bristol Advisors, LLC 51,100$174,0000.29%
RICE HALL JAMES & ASSOCIATES, LLC 2,228,059$7,575,0000.27%
NEXTHERA CAPITAL LP 200,000$680,0000.13%
LINCOLN CAPITAL CORP 37,280$127,0000.10%
Meridian Wealth Management, LLC 49,600$169,0000.07%
Rubric Capital Management LP 199,883$680,0000.07%
Virtus ETF Advisers LLC 155,009$527,0000.05%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders